<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00801216</url>
  </required_header>
  <id_info>
    <org_study_id>SCNSL1</org_study_id>
    <secondary_id>IIL-SCNSL-1</secondary_id>
    <nct_id>NCT00801216</nct_id>
  </id_info>
  <brief_title>High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement</brief_title>
  <acronym>SCNSL1</acronym>
  <official_title>High-Dose Sequential Chemotherapy and Rituximab (R-HDS) in Patients With Systemic B-Cell Lymphoma With Central Nervous System Involvement at Diagnosis or Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS San Raffaele</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mundipharma K.K.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IRCCS San Raffaele</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective trial will assess the activity and feasibility of a new high-dose
      methotrexate-based high-dose sequential chemotherapy combination in patients with B-cell
      lymphomas and CNS involvement at diagnosis or relapse. Selected drugs, with a well-documented
      anti-lymphoma activity, will be administered at high doses to increase blood-brain barrier
      penetration and CNS bioavailability as well as to reduce potential cross-resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with aggressive B-cell lymphoma and involvement of the central nervous system at
      diagnosis or relapse will be treated with a combination of high-dose methotrexate and
      high-dose cytarabine, rituximab, and intrathecal depocyte followed by rituximab-high-dose
      sequential chemotherapy supported by autologous tsem cell transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">January 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>2-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurotoxicity</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>B-Cell Lymphomas</condition>
  <arm_group>
    <arm_group_label>High-dose sequential chemoimmunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 &amp; 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose sequential chemotherapy and autologous transplant</intervention_name>
    <description>Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 &amp; 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)</description>
    <arm_group_label>High-dose sequential chemoimmunotherapy</arm_group_label>
    <other_name>Depocyte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed diagnosis of diffuse large-cell, follicular or mantle cell
             lymphoma

          2. CNS involvement (brain, meninges, cranial nerves, eyes, and/or spinal cord) at
             diagnosis or relapse after conventional chemotherapy

          3. Diagnosis of CNS involvement either by brain biopsy or CSF cytology examination.
             Neuroimaging alone is acceptable only when stereotactic biopsy is formally
             contraindicated.

          4. Age 19-65 years

          5. ECOG performance status 0-3

          6. Adequate bone marrow (PLT &gt; 100000 mm3, Hb &gt; 9 g/dl, ANC &gt; 2.000 mm3), renal
             (creatinine clearance &gt; 60 mL/min), cardiac (VEF &gt; 50%), and hepatic function (total
             serum bilirubin &lt; 3 mg/dL, AST/ALT and gammaGT &lt; 2.5 per upper normal limit value),
             within 1 week prior to study start (unless the abnormality is due to lymphoma
             involvement)

          7. Absence of symptomatic coronary artery disease, cardiac arrhythmias not well
             controlled with medication or myocardial infarction within the last 6 months (New York
             Heart Association Class III or IV heart disease)

          8. Absence of HIV infection

          9. No previous or concurrent malignancies with the exception of surgically cured
             carcinoma in-situ of the cervix and carcinoma of the skin and of other cancers without
             evidence of disease at least from 5 years

         10. Absence of any familial, sociological or geographical condition potentially hampering
             compliance with the study protocol and follow-up schedule

         11. Female patients must be non-pregnant and non-lactating. Sexually active patients of
             childbearing potential must implement adequate contraceptive measures during study
             participation

         12. No treatment with other experimental drugs within the 6 weeks previous to enrolment

         13. Give written informed consent prior to any study specific procedures, with the
             understanding that the patient has the right to withdraw from the study at any time,
             without prejudice

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés J. Ferreri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>San Raffaele Scientific Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrés J. Ferreri, MD</last_name>
    <phone>0039-02-2643 7649</phone>
    <email>andres.ferreri@hsr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefania Trinca</last_name>
    <phone>0039-02-2643 4289</phone>
    <email>stefania.trinca@hsr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>San Raffaele Scientific Institute</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Crocchiolo, MD</last_name>
      <email>roberto.crocchiolo@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Silvia Govi, MD</last_name>
      <email>silvia.govi@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Assanelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele Scientific Institute</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roberto Crocchiolo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Govi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2008</study_first_submitted>
  <study_first_submitted_qc>December 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2008</study_first_posted>
  <last_update_submitted>December 2, 2008</last_update_submitted>
  <last_update_submitted_qc>December 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2008</last_update_posted>
  <responsible_party>
    <name_title>Andrés J.M. Ferreri</name_title>
    <organization>San Raffaele Scientific Institute</organization>
  </responsible_party>
  <keyword>B-cell lymphomas</keyword>
  <keyword>lymphomatous meningitis</keyword>
  <keyword>liposomal cytarabine</keyword>
  <keyword>autologous transplant</keyword>
  <keyword>CNS involvement</keyword>
  <keyword>Secondary CNS lymphomas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

